YOU ARE EXPLORING
Lynn M. Roy, PhD
Visiting Lecturer in Pharmacology & Toxicology
Lynn Roy has experience in both industrial and academic research. In graduate school, he worked in the field of reproductive endocrinology. His dissertation examined cross-talk between cAMP/PKA and GSK3 beta / beta-catenin signaling in corpus luteum progesterone synthesis. After obtaining his doctorate, Lynn continued his research career at Novartis Pharma in Basel, Switzerland where he changed his focus and worked in the bone group researching potential treatments for osteoporosis. Upon return to the U.S., Lynn joined the laboratories of Dr. Karen Cowden Dahl and Dr. Richard Dahl at the Indiana University School of Medicine-South Bend as a postdoctoral fellow. There he worked on two different projects 1) examining the regulation of blood development by a particular microRNA, miR24 and 2) studying the role of ARID3B in ovarian cancer progression, metastasis, and relapse.
While Lynn thoroughly enjoyed bench work, he decided to attend the University of Notre Dame’s Master of Science in Patent Law program. While in the Patent Law program, he gained experience with the patenting process from disclosure to the issued patent. One of Lynn's projects was filed with the USPTO after revisions. Lynn also worked in the Intellectual Property and Entrepreneurship Clinic helping local inventors protect their inventions.
Currently, Lynn lectures at Indiana University School of Medicine-South Bend. He is a site course director for the Fundamentals of Health and Disease course and gives most of the pharmacology lectures to both the first and second year students. In addition to pharmacology, he also lectures on lipid and ethanol metabolism in the biochemistry section. Lynn also acts as a facilitator for team based learning, problem based learning, and small group exercises mainly with the first year medical students and occasionally for the case based learning with the second year students.
Lynn Roy, Karen D. Cowden Dahl. Can Stemness and Chemoresistance Be Therapeutically Targeted via Signaling Pathways in Ovarian Cancer? (2018) Cancers.
Lynn Roy, Alexander Bobbs, Rachel Sattler, Jeff L. Kurkewich, Paige B. Dausinas, Prakash Nallathamby, Karen D. Cowden Dahl. CD133 promotes adhesion to the ovarian cancer metastatic niche. (2018) Cancer Growth Metastasis.
Mitra A, Davis DA, Tomar S, et al. In vitro tumor growth of high-grade serous ovarian cancer cell lines. (2015) Gynecologic Oncology.
Lynn Roy, Emmanuel Bikorimana, Danica Lapid, Hyewon Choi, Tan Nguyen, Richard Dahl. MiR-24 is required for hematopoietic differentiation of mouse embryonic stem cells. (2015) PLOS Genetics.
Lynn Roy, Serene J. Samyesudhas, Martin Carrasco, Jun Li, Richard Dahl, and Karen D. Cowden Dahl. ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature. (2014) Oncotarget.
Serene J Samyesudhas, Lynn Roy, Jun Li, Karen Cowden Dahl. Dual roles for ARID3B in cancer: ARID3B expression in differentiated epithelium decreases during cancer while moderate expression of ARID3B in ovarian cancer predicts relapse. (2014) Gene.
Lynn Roy, Claudia A. McDonald, Chao Jiang, Anthony J. Zeleznik, Todd A. Wyatt, Xiaoying Hou, John S. Davis. Convergence of cAMP/PKA and GSK3ß/ß-catenin signaling in progesterone synthesis. (2009) Endocrinology
Indiana University School of Medicine South Bend
FS 5100 - Regional Medical Center (SB) MEDS